- Home
- REPL
REPL
Replimune Group Inc.
as 06-30-2025 3:33pm EST
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | WOBURN |
| Market Cap: | 757.8M | IPO Year: | 2018 |
| Target Price: | $20.83 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.44 - $17.00 | Next Earning Date: | 08-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Replimune Group Inc. (REPL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Patel Sushil | REPL | Chief Executive Officer | May 20 '25 | Sell | $8.06 | 25,105 | $202,346.30 | 343,576 | |
| Sarchi Christopher | REPL | Chief Commercial Officer | May 20 '25 | Sell | $8.05 | 3,749 | $30,179.45 | 128,296 | |
| Xynos Konstantinos | REPL | Chief Medical Officer | May 20 '25 | Sell | $8.06 | 7,952 | $64,093.12 | 146,933 | |
| Schwendenman Andrew | REPL | Chief Accounting Officer | May 20 '25 | Sell | $8.05 | 3,287 | $26,460.35 | 68,284 | |
| Astley-Sparke Philip | REPL | Director | May 20 '25 | Sell | $8.06 | 32,279 | $260,168.74 | 1,405,071 | |
| Hill Emily Luisa | REPL | Chief Financial Officer | May 20 '25 | Sell | $8.05 | 2,535 | $20,406.75 | 143,522 |
Latest Replimune Group Inc. News
REPL Breaking Stock News: Dive into REPL Ticker-Specific Updates for Smart Investing
MT Newswires
11 days ago
Cantor Fitzgerald Initiates Replimune Group at Overweight
GlobeNewswire
24 days ago
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
a month ago
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
a month ago
Replimune to Present at the 2025 Jefferies Global Healthcare Conference
GuruFocus.com
a month ago
Replimune Group Inc (REPL) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...
Thomson Reuters StreetEvents
a month ago
Q4 2025 Replimune Group Inc Earnings Call
GlobeNewswire
a month ago
Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
GlobeNewswire
a month ago
Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day
Compare REPL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "REPL Replimune Group Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.